Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients

Transplantation

Volumn 93, Issue 1, 2012, Pages 73-81

  Sampaio, Marcelo Santos ^a   Cho, Yong W ^a   Shah, Tariq ^a,b   Bunnapradist, Suphamai ^c   Hutchinson, Ian V ^a,d  

^a National Institute of Transplantation Los Angeles   (United States)

^b ST VINCENT MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Epstein Barr virus; Immunosuppressive drugs; Kidney transplant; Posttransplant lymphoproliferative disorder; UNOS

Indexed keywords

CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY;

ADOLESCENT; ADULT; COMORBIDITY; CYCLOSPORINE; DRUG THERAPY, COMBINATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT REJECTION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION; YOUNG ADULT;

EID: 84655170254     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31823ae7db     Document Type: Article

References (36)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
2. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: A critical reappraisal. Am J Transplant 2011; 11: 450.
3. Weikert BC, Blumberg EA. Viral infection after renal transplantation: Surveillance and management. Clin J AmSoc Nephrol 2008; 3(suppl 2): S76.
4. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823.
5. Evens AM, Roy R, Sterrenberg D, et al. Post-transplantation lymphoproliferative disorders: Diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep 2010; 12: 383.
6. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev 2010; 23: 350.
7. Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients.AmJ Transplant 2008; 8: 2205.
8. Snow AL, Martinez OM. Epstein-Barr virus: Evasive maneuvers in the development of PTLD. Am J Transplant 2007; 7: 271.
9. Anil Kumar MS, Irfan Saeed M, Ranganna K, et al. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: Fiveyear outcomes. Transpl Immunol 2008; 20: 32.
10. Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 1 year. Transplantation 2005; 80: 303.
11. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/ sirolimus in renal transplantation: Three-year analysis. Transplantation 2006; 81: 845.
12. Sampaio EL, Pinheiro-Machado PG, Garcia R, et al. Mycophenolate mofetil vs. sirolimus in kidney transplant recipients receiving tacrolimus- based immunosuppressive regimen. Clin Transplant 2008; 22: 141.
13. Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010; 28: 4740.
14. Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009; 87: 157.
15. Majewski M. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710.
16. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97: 4285.
17. Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63: 4472.
18. Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant 2008; 13: 563.
19. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004; 18: 446.
20. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581.
21. Pascual J. Post-transplant lymphoproliferative disorder-The potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22(suppl 1): i27.
22. Cullis B, D'Souza R, McCullagh P, et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006; 47: e67.
23. Iaria G, Anselmo A, De Luca L, et al. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: Case reports. Transplant Proc 2007; 39: 2036.
24. Manuelli M, De Luca L, Iaria G, et al. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation. Transplant Proc 2010; 42: 1314.
25. McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008; 8: 984.
26. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007; 7: 2619.
27. Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233.
28. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76: 597.
29. Opelz G, Döhler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222.
30. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87.
31. Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001; 71: 1065.
32. Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 2010; 149: 693.
33. van Leeuwen MT, Grulich AE, Webster AC, et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009; 114: 630.
34. Manöez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease. J Infect Dis 1997; 176: 1462.
35. Dharnidharka VR, Tejani AH, Ho PL, et al. Post-transplant lymphoproliferative disorder in the United States: Young Caucasian males are at highest risk. Am J Transplant 2002; 2: 993.
36. Meier-Kriesche HU, Chu AH, David KM, et al. Switching immunosuppression medications after renal transplantation-A common practice. Nephrol Dial Transplant 2006; 21: 2256.